Bin Chen
Clinical Sciences Bayer, China
Biography
Bin Chen is currently the Head of Clinical Sciences China in Bayer. He has the overall responsibilities to lead a team of dedicated physicians and scientists as well as a group of clinical operations in planning and conducting clinical pharmacology and experimental medicine studies in Asia (except Japan). Prior to Bayer, he was a Scientific Director within Janssen BioTherapeutics (JBIO) of Johnson & Johnson. He led teams consisting of functional area experts in biologics discovery, toxicology, translational PK/PD, bioanalysis and project management to design and execute the integrated JBIO strategy from target identification to First-in-Human (FIH). From 2015 to 2017 he served as a Director and Early Development Scientific Leader for JBIO in China, overseeing the technical and scientific aspects for Janssen’s early development efforts in China. Dr. Chen joined J&J Pharmaceutical Research & Development in 2008 as Associate Director/Director and Clinical Pharmacology Leader to support early and late-stage clinical programs in immunology, cardiovascular and metabolism therapeutic areas. He holds a BS degree in Mechanical Engineering from Nanjing University of Aeronautics and Astronautics in China. He received his PhD in Biomedical Engineering from University of Nevada, Las Vegas, and afterwards completed a post-doctoral fellowship in the Ohio State University College of Pharmacy.